Which drugs increase the risk of Clostridioides difficile infection?

Drugs That Increase Risk of C. difficile Infection

The highest-risk antibiotics for C. difficile infection are fluoroquinolones, clindamycin, third- and fourth-generation cephalosporins, and carbapenems, which should be restricted whenever possible based on local epidemiology 1.

High-Risk Antibiotics (in descending order of risk)

Tier 1: Highest Risk

• Clindamycin - historically the most notorious culprit, causing diarrhea in 21% and pseudomembranous colitis in 10% of exposed patients 2
• Fluoroquinolones - strongly associated with epidemic strains and should be primary targets for restriction 1
• Third- and fourth-generation cephalosporins - every 10 DOT/1000 patient-days increase correlates with 2.1% increase in CDI 3
• Carbapenems (especially meropenem) - every 10 DOT/1000 patient-days increase correlates with 2.9% increase in CDI 1, 3

Tier 2: Moderate Risk

• Penicillins (particularly aminopenicillins/ampicillin-based agents) 4, 2

Tier 3: Lower Risk (but still implicated)

• Macrolides 4, 2
• Sulfonamides 4, 2
• Tetracyclines/tigecycline 4, 2

Important caveat: Even single-dose surgical antibiotic prophylaxis increases CDI risk 1. The risk persists for 3 months after antibiotic cessation, with peak risk (7-10 fold increase) during therapy and the first month afterward 1.

Non-Antibiotic Medications

Proton Pump Inhibitors (PPIs)

PPIs show an epidemiologic association with CDI (OR 1.26-1.39) and should be discontinued when unnecessary, though evidence is insufficient to mandate discontinuation solely for CDI prevention 1, 2.

• Meta-analysis of 50 studies confirmed significant association between PPI use and CDI risk 2
• Risk increases further when PPIs are combined with antibiotics 2
• H2-antagonists carry lower risk than PPIs (OR 1.386 for PPIs vs H2-blockers) 2
• Clinical action: Implement PPI stewardship to stop unnecessary prescriptions, especially in high-risk patients 4, 2

NSAIDs

NSAIDs, particularly diclofenac, are associated with modest increased CDI risk (pooled OR 1.41) 5, 6.

• Diclofenac specifically shows adjusted OR 1.35 (95% CI 1.10-1.67) 6
• Other NSAIDs do not show the same association 6
• Clinical action: Consider alternative NSAIDs in patients at high CDI risk

Cancer Chemotherapy

Chemotherapeutic agents increase CDI risk through both antibiotic activity and immunosuppressive effects (neutropenia) 1.

Critical Risk Modifiers

Duration and Intensity Matter

• Antibiotic treatment >10 days significantly increases risk 2
• Multiple antibiotic classes compound the risk 1
• Each 50 DOT/1000 patient-days increase in total antibiotic use = 4.4% increase in CDI 3
• Antibiotic spectrum intensity (measured by ASI) shows RR 1.09 per unit increase 7

Continued Antibiotic Use During CDI

Continuing antibiotics for other infections during CDI treatment significantly increases recurrence risk 4.

Safer alternatives if antibiotics must continue:

• Parenteral aminoglycosides
• Sulfonamides
• Macrolides
• Vancomycin
• Tetracycline/tigecycline 4

Stewardship Implications

Hospitals that achieved ≥30% reduction in total antibiotic use saw 33% decrease in CDI; ≥20% reduction in fluoroquinolones or third-/fourth-generation cephalosporins resulted in 8% and 13% CDI reduction respectively 3.

Priority Targets for Restriction

1. Fluoroquinolones (except when no alternatives exist)
2. Clindamycin (avoid entirely if possible)
3. Third-/fourth-generation cephalosporins (except surgical prophylaxis)
4. Minimize duration and number of agents prescribed 1

Common pitfall: Metronidazole, despite being a CDI treatment, paradoxically shows association with CDI in IBD populations (OR 3.6) and outpatient settings 8, 9. This likely reflects confounding by indication but warrants awareness.